Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

A subset of colorectal cancer (CRC) with a mesenchymal phenotype (CMS4) displays an aggressive disease, with an increased risk of recurrence after surgery, reduced survival, and resistance to standard treatments. It has been shown that the AXL and TGFβ signaling pathways are involved in epithelial-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, Davide, Blauensteiner, Bernadette, Matrone, Nunzia, Belli, Valentina, Mohr, Thomas, Vitiello, Pietro Paolo, Martini, Giulia, Poliero, Luca, Cardone, Claudia, Napolitano, Stefania, De Falco, Vincenzo, Giunta, Emilio Francesco, Ciaramella, Vincenza, Corte, Carminia della, Barra, Giusi, Selvaggi, Francesco, Franco, Renato, Marino, Federica Zito, Cuomo, Antonio, Morgillo, Floriana, Troiani, Teresa, Sibilia, Maria, Ciardiello, Fortunato, Martinelli, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878213/
https://www.ncbi.nlm.nih.gov/pubmed/33570712
http://dx.doi.org/10.1007/s12032-021-01464-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878213/
https://www.ncbi.nlm.nih.gov/pubmed/33570712
http://dx.doi.org/10.1007/s12032-021-01464-3

Ejemplares similares